These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

53 related items for PubMed ID: 9051132

  • 1. [Phase II study of combination chemotherapy with cisplatin, carboplatin and etoposide (CPVP) in unresectable non-small cell lung cancer: analysis of survival time and prognostic factors].
    Sakurai M, Ichiki M, Hayashi I.
    Gan To Kagaku Ryoho; 1997 Feb; 24(3):303-8. PubMed ID: 9051132
    [Abstract] [Full Text] [Related]

  • 2. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D, Golubicic I, Gavrilovic D, Kezic I, Jelic S.
    J BUON; 2009 Feb; 14(2):203-9. PubMed ID: 19650167
    [Abstract] [Full Text] [Related]

  • 3. [Phase II study of a novel combination regimen composed of cisplatin, carboplatin and etoposide against unresectable non-small cell lung cancer].
    Sakurai M, Ichiki M, Ohashi Y, Hayashi I.
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):499-502. PubMed ID: 8383950
    [Abstract] [Full Text] [Related]

  • 4. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX, Chen XB.
    Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC, McCrystal MR, Christmas TI.
    N Z Med J; 1998 Nov 27; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [Abstract] [Full Text] [Related]

  • 9. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 27; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 10. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumöhl J, Schmerber J, Koumakis G, Florin MC, Zacharias C, Berghmans T, Mommen P, Ninane V, Klastersky J.
    Br J Cancer; 2000 Nov 27; 83(9):1128-35. PubMed ID: 11027424
    [Abstract] [Full Text] [Related]

  • 11. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT.
    Semin Oncol; 1997 Aug 27; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
    [Abstract] [Full Text] [Related]

  • 12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 27; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 13. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U.
    Lung Cancer; 2006 Jul 27; 53(1):67-75. PubMed ID: 16713013
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I.
    Cas Lek Cesk; 2005 Jul 27; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [Abstract] [Full Text] [Related]

  • 19. A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
    Rosell R, Felip E, Massuti B, González-Larriba JL, Benito D, López-Cabrerizo MP, Salamanca O, Camps C, Puerto-Pica J.
    Semin Oncol; 1997 Aug 27; 24(4 Suppl 12):S12-56-S12-60. PubMed ID: 9331123
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.